Gastrointestinal Stromal Tumor (GIST) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Gastrointestinal stromal tumors (GISTs) belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea, and vomiting, vomiting blood or having blood in the stool, and fatigue due to anemia. Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy, and chemotherapy.

The gastrointestinal stromal tumor drugs in development market research report provides an overview of the GIST pipeline landscape. The report provides comprehensive information on the therapeutics under development for GIST, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for GIST and features dormant and discontinued projects.

What are the targets of the GIST pipeline drugs market?

Some of the targets of the GIST pipeline drugs market are Mast/Stem Cell Growth Factor Receptor Kit, Platelet Derived Growth Factor Receptor Alpha, Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 3, Platelet Derived Growth Factor Receptor Beta, Receptor Type Tyrosine Protein Kinase FLT3, Vascular Endothelial Growth Factor Receptor 1, Programmed Cell Death Protein 1, Fibroblast Growth Factor Receptor 1, and Fibroblast Growth Factor Receptor 2.

GIST pipeline drugs market, by targets

For more target insights, download a free report sample

What are the mechanisms of action of the GIST pipeline drugs market?

Some of the mechanisms of action of the GIST pipeline drugs market are Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Platelet Derived Growth Factor Receptor Alpha Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Platelet Derived Growth Factor Receptor Beta Inhibitor, Programmed Cell Death Protein 1 Antagonist, Cytotoxic To Cells Expressing Mast/Stem Cell Growth Factor Receptor Kit, and Fibroblast Growth Factor Receptor 1 Inhibitor.

GIST pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in the GIST pipeline drugs market?

The routes of administration in the GIST pipeline drugs market are oral, intravenous, subcutaneous, intratumor, parenteral, intravenous drip, inhalational, intradermal, intravesical, ophthalmic, and topical.

GIST pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What are the molecule types in the GIST pipeline drugs market?

The molecule types in the GIST pipeline drugs market are small molecule, monoclonal antibody, monoclonal antibody conjugated, cell therapy, oncolytic virus, synthetic peptide, antisense oligonucleotide, gene-modified cell therapy, oligonucleotide, peptide, and recombinant protein.

GIST pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key companies in the GIST pipeline drugs market?

Some of the key companies in the GIST pipeline drugs market are Deciphera Pharmaceuticals Inc, Novartis AG, Bayer AG, Blueprint Medicines Corp, CStone Pharmaceuticals Co Ltd, Merck & Co Inc, Novelty Nobility Inc, Pfizer Inc, AB Science SA, and ABL Bio Inc.

GIST pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

This report provides:

• A snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST).
• Reviews of pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
• Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• Key companies involved in Gastrointestinal Stromal Tumor (GIST) therapeutics and enlists all their major and minor projects.
• Evaluation of Gastrointestinal Stromal Tumor (GIST) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• All the dormant and discontinued pipeline projects.
• Reviews of the latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST).

Reasons to Buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST).
• Identify potential new clients or partners in the target demographic.
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics.
• Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.